Overview

Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma

Status:
Active, not recruiting

Trial end date:
2022-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this trial is to determine 1. Objective response rate (ORR), defined as the proportion of patients having CR, CRr or PR in the centrally reviewed restaging after six cycles of chemotherapy 2. Progression-free survival (PFS) 3 years after registration

Phase:

Phase 2

Details

Lead Sponsor:

University of Cologne

Treatments:

Antibodies, Monoclonal
Brentuximab Vedotin
Cyclophosphamide
Doxorubicin